Clinical trials
Recherche d’études cliniques
Recherchez uniquement dans les études cliniques enregistrées dans Biomedical Watch.
Études cliniques 3370
| Étude / NCT ⇅ | Molécule ⇅ | Maladie ⇅ | Phase ⇅ | Statut ⇅ | Résultat ⇅ | Sponsor ⇅ | Pays / centres ⇅ | Période ⇅ | Détail |
|---|---|---|---|---|---|---|---|---|---|
| NCT05799378 SHIELD — Effects of Stopping Hydroxychloroquine in Elderly Lupus Disease |
Hydroxychloroquine | Lupus | Phase 3 | RECRUITING | En attente / non publié | NYU Langone Health | United States · Columbia University Irving Medical Ce… | 2024-06-27 → 2029-06-30 | Ouvrir |
| NCT06984341 A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharma… |
P-CD19CD20-ALLO1 Cells | Lupus | Phase 1 | WITHDRAWN | En attente / non publié | Genentech, Inc. | United States · University of Alabama at Birmingham: … | 2026-06-30 → 2033-11-01 | Ouvrir |
| NCT05039619 POSTERITY — A Study to Evaluate the Efficacy, Safety, and Pharmacokinet… |
Obinutuzumab | Lupus | Phase 2 | RECRUITING | En attente / non publié | Hoffmann-La Roche | United States, Brazil, Canada, France, Italy, Mexico,… | 2022-05-12 → 2030-06-14 | Ouvrir |
| NCT05039840 APATURA — Efficacy and Safety of Frexalimab (SAR441344) in the Treatmen… |
SAR441344 IV | Lupus | Phase 2 | ACTIVE_NOT_RECRUITING | En attente / non publié | Sanofi | United States, Argentina, Brazil, Chile, Georgia, Gre… | 2021-11-10 → 2026-11-24 | Ouvrir |
| NCT07409181 A Study to Test Whether Different Doses of BI 3000202 Help People With … |
BI 3000202 | Lupus | Phase 2 | RECRUITING | En attente / non publié | Boehringer Ingelheim | United States, Argentina, Australia, Brazil, Bulgaria… | 2026-04-20 → 2029-07-08 | Ouvrir |
| NCT07749430 A Clinical Study of ACG102 Injection in Patients With Refractory Active… |
ACG102 Injection | Lupus | Phase 1 | NOT_YET_RECRUITING | En attente / non publié | Union Hospital, Tongji Medical Co… | Non communiqué | 2026-09-15 → 2028-01-30 | Ouvrir |
| NCT06617325 PHOENYCS FLY — A Study to Evaluate the Efficacy and Safety of Dapiroliz… |
DZP | Lupus | Phase 3 | RECRUITING | En attente / non publié | UCB Biopharma SRL | United States, Argentina, Belgium, Canada, Chile, Chi… | 2024-11-21 → 2028-05-31 | Ouvrir |
| NCT07751315 A Study of QLS2404 Injection in Healthy Participants and Participants W… |
Ia:QLS2404 very low dose | Lupus | Phase 1 | NOT_YET_RECRUITING | En attente / non publié | Qilu Pharmaceutical Co., Ltd. | China · West China Hospital of Sichuan University, Ch… | 2026-08-11 → 2028-06-30 | Ouvrir |
| NCT07629583 To Evaluate the Effects of Cevostamab in Participants With Systemic Lup… |
Cevostamab | Lupus | Phase 1 | RECRUITING | En attente / non publié | Genentech, Inc. | Spain · Hospital Universitario Virgen Macarena, Sevil… | 2026-10-31 → 2030-03-29 | Ouvrir |
| NCT06570798 A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Au… |
Inebilizumab | Lupus | Phase 2 | RECRUITING | En attente / non publié | Amgen | United States, Australia, Belgium, France, Germany, I… | 2025-07-16 → 2028-08-06 | Ouvrir |
| NCT04481633 PREPCOV — Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine o… |
PREPCOV — Efficacy of Pre-exposur… | Lupus | Non applicable | COMPLETED | En attente / non publié | University Hospital, Toulouse | France · Haut-Lévêque Hospital - Gastro-entérologie, … | 2020-09-09 → 2022-12-06 | Ouvrir |
| NCT07483346 IASO-782 in Systemic Lupus Erythematosus |
IASO-782 injection | Lupus | Phase 1 | RECRUITING | En attente / non publié | Shanghai IASO Biotechnology Co., … | China · Affiliated Hangzhou First People's Hospital, … | 2026-05-26 → 2028-05-31 | Ouvrir |
| NCT06977724 A Study to Assess Adverse Events, How the Drug Moves Through the Body a… |
ABBV-319 | Lupus | Phase 1 | RECRUITING | En attente / non publié | AbbVie | United States, France, Netherlands · Advanced Quality… | 2025-08-26 → 2029-03 | Ouvrir |
| NCT07180537 Creating Health Course Study for People With Rheumatological Conditions… |
Creating Health Course Study for … | Lupus | Non applicable | RECRUITING | En attente / non publié | Terry L. Wahls | United States · Univeristy of Iowa, Iowa City, United… | 2025-12-01 → 2027-12-31 | Ouvrir |
| NCT06161116 Efficacy and Safety of MK-6194 in Adult Participants With Systemic Lupu… |
MK-6194 | Lupus | Phase 2 | TERMINATED | En attente / non publié | Merck Sharp & Dohme LLC | United States, Argentina, Brazil, Canada, Chile, Chin… | 2023-12-27 → 2025-07-30 | Ouvrir |
| NCT05879718 A Study to Learn About the Study Medicine (PF-06823859) in Adults With … |
PF-06823859 | Lupus | Phase 2 | TERMINATED | En attente / non publié | Pfizer | United States, Canada, Greece, Spain · Cleveland Clin… | 2023-07-07 → 2025-11-18 | Ouvrir |
| NCT06144710 SG301-SC Injection Safety Study in Subjects With Systemic Lupus Erythem… |
SG301 SC Injection | Lupus | Phase 1 | COMPLETED | En attente / non publié | Hangzhou Sumgen Biotech Co., Ltd. | China · First Affiliated Hospital of Xiamen Universit… | 2023-11-10 → 2026-01-07 | Ouvrir |
| NCT06795893 The Anifrolumab PRIM Program |
Anifrolumab | Lupus | À vérifier | RECRUITING | En attente / non publié | AstraZeneca | Sweden · Reseach Facility, Södertälje, Sweden | 2025-11-07 → 2031-04-15 | Ouvrir |
| NCT07694336 A Study of Quinacrine in Participants With Cutaneous Lupus Erythematosus |
Quinacrine Hydrochloride | Lupus | Phase 2 | RECRUITING | En attente / non publié | Victoria Werth | United States · Hospital of the University of Pennsyl… | 2026-06-30 → 2028-06-30 | Ouvrir |
| NCT07760480 MAPLE — Assessing Residual Inflammation and Macrophage Presence in Lupu… |
Kidney Biopsy | Lupus | Phase 4 | RECRUITING | En attente / non publié | National Cancer Institute (NCI) | Netherlands · Amsterdam University Medical Center, Am… | 2026-04-23 → 2030-04 | Ouvrir |
| NCT07203157 HEAL-SLE: Holistic Energy for Alleviating Lupus Symptoms |
HEAL-SLE: Holistic Energy for All… | Lupus | Non applicable | ACTIVE_NOT_RECRUITING | En attente / non publié | NYU Langone Health | United States · NYU Langone Health, New York, United … | 2026-03-03 → 2026-10-31 | Ouvrir |
| NCT07523282 AID — Safety and Preliminary Efficacy of HN2302 in Patients With Autoim… |
HN2302 Injection | Lupus | Phase 1 | NOT_YET_RECRUITING | En attente / non publié | The Affiliated Hospital of Xuzhou… | China · The First Affiliated Hospital of University o… | 2026-12-31 → 2028-06-30 | Ouvrir |
| NCT07760155 A Phase 2 Study on the Safety and Efficacy of the Anti-BAFF-R Monoclona… |
ESG206 | Lupus | Phase 2 | NOT_YET_RECRUITING | En attente / non publié | Shanghai Escugen Biotechnology Co… | China · Affiliated Hospital of Hebei Engineering Univ… | 2026-09-01 → 2028-09-30 | Ouvrir |
| NCT06801119 SLE，SSc，RA — Efficacy and Safety of HN2301 in Autoimmune Diseases（AIDs） |
HN2301 injection | Lupus | Phase 1 | RECRUITING | En attente / non publié | Shenzhen MagicRNA Biotechnology C… | China · The First Affiliated Hospital of University o… | 2025-03-16 → 2028-06-30 | Ouvrir |
| NCT06975787 Dose Escalation Study With Bispecific Antibodies in Adult Participants … |
Vonsetamig | Lupus | Phase 1 | RECRUITING | En attente / non publié | Regeneron Pharmaceuticals | United States, France, Germany, South Korea, Spain, T… | 2025-12-22 → 2029-09-10 | Ouvrir |